The Current Ratio as of December 2024 (TTM) for KalVista Pharmaceuticals, Inc. (KALV) is 6.87

According to KalVista Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 6.87. This represents a change of -10.66% compared to the average of 7.69 of the last 4 quarters.

KalVista Pharmaceuticals, Inc. (KALV) Historical Current Ratio (quarterly & annually)

How has KALV Current Ratio performed in the past?

The mean historical Current Ratio of KalVista Pharmaceuticals, Inc. over the last ten years is 10.52. The current 6.87 Current Ratio has changed 6.43% with respect to the historical average. Over the past ten years (40 quarters), KALV's Current Ratio was at its highest in in the July 2021 quarter at 30.35. The Current Ratio was at its lowest in in the March 2015 quarter at 0.39.

KalVista Pharmaceuticals, Inc. (KALV) Current Ratio by Quarter and Year

Discovering the peaks and valleys of KalVista Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

KalVista Pharmaceuticals, Inc. (KALV) Average Current Ratio

How has KALV Current Ratio performed in the past?

The current Current Ratio of KalVista Pharmaceuticals, Inc. (KALV) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

KalVista Pharmaceuticals, Inc. (KALV) Current Ratio vs. Peers

How is KALV’s Current Ratio compared to its peers?

KalVista Pharmaceuticals, Inc.’s Current Ratio is less than Crinetics Pharmaceuticals, Inc. (16.38), less than Theseus Pharmaceuticals, Inc. (29.93), less than Kura Oncology, Inc. (11.47), less than Viridian Therapeutics, Inc. (18.55), less than Replimune Group, Inc. (10.11), greater than Nuvectis Pharma, Inc. (2.74), greater than Lyra Therapeutics, Inc. (3.64), less than Kronos Bio, Inc. (8.32), greater than Gossamer Bio, Inc. (6.74), less than Syndax Pharmaceuticals, Inc. (6.99), greater than Cogent Biosciences, Inc. (6.44), less than Cullinan Oncology, Inc. (24.46), greater than Mersana Therapeutics, Inc. (2.35), greater than Immunocore Holdings plc (3.78), greater than Mirum Pharmaceuticals, Inc. (3.34), less than Larimar Therapeutics, Inc. (13.10), less than Cytokinetics, Incorporated (9.28), less than DICE Therapeutics, Inc. (38.14), less than Edgewise Therapeutics, Inc. (26.35), less than Karuna Therapeutics, Inc. (19.31), less than Dyne Therapeutics, Inc. (17.02),

Build a custom stock screener for KalVista Pharmaceuticals, Inc. (KALV) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like KalVista Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

KalVista Pharmaceuticals, Inc. (KALV) and other stocks custom spreadsheet templates

The easiest way to analyze a company like KalVista Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.